MilliporeSigma and The Michael J. Fox Foundation Offer Service to Advance Parkinson’s Research
- SMC® immunoassay technology from Merck detects small changes in biomarker levels, indicating level of cell dysfunction
- New understanding of cell dysfunction contributes to future therapeutics aimed at slowing disease progression
- Merck’s service offered through support from MJFF is key to accelerating a path for improved treatment of Parkinson’s disease
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618617534/en/
(Photo: Business Wire)
“Using the SMCxPRO® immunoassay technology to assess cell dysfunction represents a significant step forward in developing new treatment options for people fighting PD,” said
The research is focused on the biomarker pS65 ubiquitin (pS65-Ub). PD is a neurodegenerative disease that predominantly affects certain nerve cells in a specific area of the brain. By the time motor symptoms become visible, 60% to 80% of these cells have already been lost or impaired. Before that, affected cells stop functioning properly, which ultimately leads to their death. One readout of dysfunction in these cells is pS65-Ub. Extremely sensitive test methods are required to detect it. Using the SMCxPRO® immunoassay platform, used to quantify levels of a specific target within a sample, scientists can now detect small concentrations of pS65-Ub. This helps, for the first time, to track the response of different therapeutic options on disease progression.
“Ultrasensitive assays allow us to research multiple biomarkers we know play a role in disease progression. These would be valuable to diagnose and stratify patients and for future therapeutic development. Current known therapies for PD can treat symptoms but do not slow or halt disease progression. We are hopeful this collaboration will contribute to improved quality of life for patients,” said
Currently, PD impacts around 10 million people worldwide. Its prevalence has doubled in the past 25 years, making it the fastest-growing neurological condition in the world. The number of people with the disease is expected to further grow to 20 million by the year 2050. MilliporeSigma’s contribution to Parkinson research has been recognized by CiteAb Awards, based on being the company with the most citations related to Parkinson’s research in 2023.
About the Life Science business of
The Life Science business of
Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023,
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are
Follow
All
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618617534/en/
Media Relations
rachel.bloom-baglin@milliporesigma.com
Phone: +1 978 436 1725
Source: